Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults. (2nd December 2017)

• Record Type: Journal Article
• Authors: Kallur, Lakshmi; Gonzalez-Estrada, Alexei; Eidelman, Frank; Dimov, Ves
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 13:Number 12(2017:Dec.)
• Page Start: 1275
• Page End: 1280
• Publication Date: 2017-12-02
• Subjects: Mepolizumab -- eosinophilic asthma -- monoclonal -- asthma -- treatment; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2017.1406919
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Mepolizumab is a humanized monoclonal antibody that binds to and inactivates IL-5. It is available as a subcutaneous preparation. The practical application of mepolizumab is as an add-on therapy in the treatment of severe eosinophilic asthma. Areas covered : This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of adults. The articles that have been selected evaluate the use of mepolizumab and its role in eosinophilic asthma. Expert opinion : Mepolizumab is significantly more effective than placebo in reducing exacerbations and need for systemic corticosteroids in severe eosinophilic asthma. There is a lack of head to head studies comparing mepolizumab to other monoclonal anti-IL-5 inhibitors in severe eosinophilic asthma. Post marketing surveillance revealed risk of anaphylaxis that is below 1%.